{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cytotoxicity", "Docetaxel", "Prostate cancer", "Solid lipid nanoparticles", "Targeted drug delivery"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34400962", "DateRevised": {"Year": "2021", "Month": "08", "Day": "18"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.22037/ijpr.2020.113436.14302"], "Journal": {"ISSN": "1735-0328", "JournalIssue": {"Volume": "20", "Issue": "1", "PubDate": {"Year": "2021", "Season": "Winter"}}, "Title": "Iranian journal of pharmaceutical research : IJPR", "ISOAbbreviation": "Iran J Pharm Res"}, "ArticleTitle": "Targeting Solid Lipid Nanoparticles with Anisamide for Docetaxel Delivery to Prostate Cancer: Preparation, Optimization, and <i>In-vitro</i> Evaluation.", "Pagination": {"StartPage": "327", "EndPage": "338", "MedlinePgn": "327-338"}, "Abstract": {"AbstractText": ["The purpose of the current study was to prepare and characterize the targeted solid lipid nanoparticles (SLNs) containing docetaxel (DTX) for prostate cancer treatment. The goal has been achieved by locating anisamide (Anis) ligand on the surface of SLNs, which can interact with the overexpressed sigma receptor on the prostate cancer cells. DTX loaded SLNs were prepared by high shear homogenization and ultra-sonication method and optimized by applying experimental design. The average particle size and the entrapment efficiency of the optimum DTX-SLN were 174 \u00b1 9.1 nm and 83 \u00b1 3.34%, respectively. The results of differential scanning calorimetry showed that DTX had been dispersed as amorphous in the nanocarriers. Scanning electron microscopy (SEM) images confirmed the nanoscale size and spherical shape of the nanoparticles. The cytotoxicity studies have demonstrated that IC<sub>50</sub> of free drug, DTX-SLN and DTX-SLN-Anis was 0.25 \u00b1 0.01, 0.23 \u00b1 0.02, 0.12 \u00b1 0.01 nM on PC3 cell line and 20.9 \u00b1 3.89, 18.74 \u00b1 7.43, and 14.68 \u00b1 5.70 nM on HEK293 cell line, respectively. Targeted DTX-SLN-Anis was acted more effectively on prostate cancer cells in comparison to DTX-SLN and free drug. The results of this study have depicted that the anti-cancer drug loaded in targeted SLNs can be a promising way for cancer treatment. In addition, performing <i>in-vivo</i> studies will be complementary to these findings."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Jalilian", "ForeName": "Milad", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Derakhshandeh", "ForeName": "Katayoun", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Nanotechnology Research Center (ZPNRC), Zanjan University of Medical Sciences, Zanjan, Iran."}], "LastName": "Kurd", "ForeName": "Masoumeh", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Lashani", "ForeName": "Hussein", "Initials": "H"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Iran J Pharm Res", "NlmUniqueID": "101208407", "ISSNLinking": "1726-6882"}}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Eng. J. Med. . 2004;351:1513\u201320.", "ArticleIdList": ["15470214"]}, {"Citation": "March B, Faulkner S, Jobling P, Steigler A, Blatt A, Denham J, Hondermarck\u00a0H Tumour innervation and neurosignalling in prostate cancer. Nat. Rev. Urol. . 2020;17:119\u201330.", "ArticleIdList": ["31937919"]}, {"Citation": "Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. . 1995;55:408\u201313.", "ArticleIdList": ["7812973"]}, {"Citation": "John CS, Bowen WD, Fisher SJ, Lim BB, Geyer BC, Vilner BJ, Wahl RL. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1\u2032-piperidinyl) ethyl]-3-[125I] iodo-4-methoxybenzamide (P [125I] MBA) for imaging breast cancer. Nucl. Med. Biol. . 1999;26:377\u201382.", "ArticleIdList": ["10382840"]}, {"Citation": "John CS, Vilner BJ, Bowen WD. Synthesis and Characterization of -N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide, a New sigma Receptor Radiopharmaceutical: High-Affinity Binding to MCF-7 Breast Tumor Cells. J. Med. Chem. . 1994;37:1737\u20139.", "ArticleIdList": ["8021913"]}, {"Citation": "Hou C, Tu Z, Mach R, Kung HF, Kung MP. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl. Med. Biol. . 2006;33:203\u20139.", "ArticleIdList": ["16546674"]}, {"Citation": "John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting sigma receptor-binding benzamides as in-vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res. . 1999;59:4578\u201383.", "ArticleIdList": ["10493511"]}, {"Citation": "Dasargyri A, K\u00fcmin CD, Leroux JC. Targeting nanocarriers with anisamide: fact or artifact? Adv. Mater. . 2017;29:1603451.", "ArticleIdList": ["27885719"]}, {"Citation": "Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev. Urol. . 2006;8:S48\u201355.", "ArticleIdList": ["PMC1578715", "17021642"]}, {"Citation": "Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst. . 1991;83:288\u201391.", "ArticleIdList": ["1671606"]}, {"Citation": "Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry . 1993;32:2747\u201355.", "ArticleIdList": ["8096151"]}, {"Citation": "Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. . 1980;77:1561\u20135.", "ArticleIdList": ["PMC348536", "6103535"]}, {"Citation": "Sadegh Malvajerd S, Azadi A, Izadi Z, Kurd M, Dara T, Dibaei M, Sharifzadeh M, Akbari Javar H, Hamidi M. Brain delivery of curcumin using solid lipid nanoparticles and nanostructured lipid carriers: Preparation, optimization, and pharmacokinetic evaluation. ACS Chem. Neurosci. . 2018;10:728\u201339.", "ArticleIdList": ["30335941"]}, {"Citation": "Omwoyo WN, Ogutu B, Oloo F, Swai H, Kalombo L, Melariri P, Maroa Mahanga G, Waweru Gathirwa\u00a0J. Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles. Int. J. Nanomedicine . 2014;9:3865\u201374.", "ArticleIdList": ["PMC4137995", "25143734"]}, {"Citation": "Dasargyri A, Hervella P, Christiansen A, Proulx ST, Detmar M, Leroux JC. Findings questioning the involvement of Sigma-1 receptor in the uptake of anisamide-decorated particles. J. Control. Release . 2016;224:229\u201338.", "ArticleIdList": ["26774218"]}, {"Citation": "Bhatt S, Sharma J, Singh M, Saini V. Solid lipid nanoparticles: a promising technology for delivery of poorly water-soluble drugs. Acta Pharm. Sci. . 2018;56:27\u201349."}, {"Citation": "Derakhshandeh K, Hosseinalizadeh A, Nikmohammadi M. The effects of PLGA microparticles on intestinal absorption of p-glycoprotein substrate using the everted rat intestinal sac model. Arch. Pharmacal. Res. . 2011;34:1989\u201397.", "ArticleIdList": ["22139699"]}, {"Citation": "Perez MH, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffman M, Bodmeier R, Maincent P. The preparation and evaluation of poly (\u03b5-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J. Control. Release . 2000;65:429\u201338.", "ArticleIdList": ["10699300"]}, {"Citation": "S\u00e1nchez E, Moreno A, Vicent M, Salvador M, Bonache V, Klyatskina E, Santacruz I, Moreno R. Preparation and spray drying of Al2O3\u2013TiO2 nanoparticle suspensions to obtain nanostructured coatings by APS. Surf. Coat. Tech. . 2010;205:987\u201392."}, {"Citation": "Smith G. Bioanalytical method validation: notable points in the 2009 draft EMA Guideline and differences with the 2001 FDA Guidance. Bioanalysis. . 2010;2:929\u201335.", "ArticleIdList": ["21083222"]}, {"Citation": "Ahmadi F, Derakhshandeh K, Jalalizadeh A, Mostafaie A, Hosseinzadeh L. Encapsulation in PLGA-PEG enhances 9-nitro-camptothecin cytotoxicity to human ovarian carcinoma cell line through apoptosis pathway. Res. Pharm. Sci. . 2015;10:161\u20138.", "ArticleIdList": ["PMC4584455", "26487893"]}, {"Citation": "Lee E, Kim H, Lee IH, Jon S. In-vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J. Control. Release . 2009;140:79\u201385.", "ArticleIdList": ["19712714"]}, {"Citation": "Owuor JJ, Oloo F, Ouma D, Omwoyo WN. Optimization and Characterization of PrimaquineLoaded solid lipid nanoparticles (SLN) for liver schinonticide targeting by freeze drying. Drug Des. Dev. Ther. . 2017;1:104\u201312."}, {"Citation": "Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in-vivo evaluations. J. Pharm. Sci. . 2013;102:1994\u20132004.", "ArticleIdList": ["23558514"]}, {"Citation": "Bijari N, Ghobadi S, Derakhshandeh K. Irinotecan binds to the internal cavity of beta-lactoglobulin: A multi-spectroscopic and computational investigation. J. Pharm. Biomed. Anal. . 2017;139:109\u201315.", "ArticleIdList": ["28279925"]}, {"Citation": "Saghafi Z, Mohammadi M, Mahboobian MM, Derakhshandeh K. Preparation, characterization, and in-vivo evaluation of perphenazine-loaded nanostructured lipid carriers for oral bioavailability improvement. Drug Dev. Ind. Pharm. . 2021;47:509\u201320.", "ArticleIdList": ["33650445"]}, {"Citation": "Zhang L, Zhang N. How nanotechnology can enhance docetaxel therapy. Int. J. Nanomedicine . 2013;8:2927\u201341.", "ArticleIdList": ["PMC3742154", "23950643"]}, {"Citation": "M\u00fcller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. . 2001;47:3\u201319.", "ArticleIdList": ["11251242"]}, {"Citation": "Ling D, Hackett MJ, Hyeon T. Surface ligands in synthesis, modification, assembly and biomedical applications of nanoparticles. Nano Today . 2014;9:457\u201377."}, {"Citation": "Owen SC, Chan DP, Shoichet MS. Polymeric micelle stability. Nano Today . 2012;7:53\u201365."}, {"Citation": "Pawar H, Surapaneni SK, Tikoo K, Singh C, Burman R, Gill MS, Suresh S. Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: in-vitro evaluation, pharmacokinetic and biodistribution in rats. Drug Deliv. . 2016;23:1453\u201368.", "ArticleIdList": ["26878325"]}, {"Citation": "Bell S, Subhashini S. Self-assembled Chitosan-g-Poly (itaconic acid) nanoparticles: a potential drug carrier for docetaxel. Asian J. Chem. . 2018;30:1469\u201375."}, {"Citation": "Oktay B. Preparation of stearic acid/graphene oxide based form-stable composite phase change materials. Marmara Fen Bilimleri Dergisi . 2018;2:119\u201325."}, {"Citation": "Aboutaleb E, Atyabi F, Khoshayand MR, Vatanara AR, Ostad SN, Kobarfard F, Dinarvand R. Improved brain delivery of vincristine using dextran sulfate complex solid lipid nanoparticles: optimization and in-vivo evaluation. J. Biomed. Mater. Res. . 2014;102:2125\u201336.", "ArticleIdList": ["23893939"]}, {"Citation": "Ghori MU, Conway BR. Hydrophilic matrices for oral control drug delivery. Am. J. Pharmacol. Sci. . 2015;3:103\u20139."}, {"Citation": "Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer . 2004;112:693\u2013700.", "ArticleIdList": ["15382053"]}, {"Citation": "Urandur S, Banala VT, Shukla RP, Mittapelly N, Pandey G, Kalleti N, Mitra K, Rath SK, Trivedi R, Ramarao P\u00a0and Mishra PR. Anisamide-anchored lyotropic nano-liquid crystalline particles with AIE effect: a smart optical beacon for tumor imaging and therapy. ACS Appl. Mater. Interfaces . 2018;10:12960\u201374.", "ArticleIdList": ["29577719"]}, {"Citation": "Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Xi Y, Li Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials . 2009;30:226\u201332.", "ArticleIdList": ["18851881"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "17", "Hour": "7", "Minute": "28"}, {"Year": "2021", "Month": "8", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "18", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "1", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34400962", "PMC8170742", "10.22037/ijpr.2020.113436.14302"]}}], "PubmedBookArticle": []}